Macrolide antiinfective agents
    52.
    发明授权
    Macrolide antiinfective agents 有权
    大环内酯类抗感染药

    公开(公告)号:US06593302B2

    公开(公告)日:2003-07-15

    申请号:US10075466

    申请日:2002-02-13

    CPC classification number: C07H17/08 Y02P20/55

    Abstract: Compounds of the formula wherein Ra is H; substituted or unsubstituted alkyl (1-10C); substituted or unsubstituted alkenyl (2-10C); substituted or unsubstituted alkynyl (2-10C); substituted or unsubstituted aryl (4-14C); substituted or unsubstituted arylalkyl (5-20C); or ORa is replaced by H; Rb is H or halogen; Rc is H or a protecting group; Rd is methyl, unsubstituted alkyl (3-10C); substituted alkyl (1-10C); substituted or unsubstituted alkynyl (2-10C); substituted or unsubstituted aryl (4-14C); substituted or unsubstituted arylalkyl (5-20C); substituted or unsubstituted arylalkenyl (5-20C); substituted or unsubstituted arylalkynyl (5-20C); substituted or unsubstituted amidoarylalkyl (5-20C); substituted or unsubstituted amidoarylalkenyl (5-20C); or substituted or unsubstituted amidoarylalkynyl (5-20C); Re is H or a protecting group; L is methylene or carbonyl; T is —O—, —N(R)—, —N(OR)—, —N(NHCOR)—, —N(N═CHR)—, or —N(NHR)— wherein R is H or Ra as defined above, with the proviso that when L is methylene, T is —O—; one of Z and Y is H and the other is OH, protected OH, or amino, mono- or dialkylamino, protected amino, or an amino heterocycle or Z and Y together are ═O, ═NOH or a derivatized oxime; including any pharmaceutically acceptable salts thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof, are antimicrobial agents.

    Abstract translation: 化学式R a的化合物是H; 取代或未取代的烷基(1-10C); 取代或未取代的烯基(2-10C); 取代或未取代的炔基(2-10C); 取代或未取代的芳基(4-14C); 取代或未取代的芳基烷基(5-20​​℃); 或ORa被H代替; Rb是H或卤素; Rc是H或保护基; Rd是甲基,未取代的烷基(3-10C); 取代的烷基(1-10C); 取代或未取代的炔基(2-10C); 取代或未取代的芳基(4-14C); 取代或未取代的芳基烷基(5-20​​℃); 取代或未取代的芳基烯基(5-20​​℃); 取代或未取代的芳基炔基(5-20​​℃); 取代或未取代的酰氨基芳基烷基(5-20​​℃); 取代或未取代的酰氨基芳基烯基(5-20​​℃); 或取代或未取代的酰氨基芳基炔基(5-20​​℃); Re是H或保护基; L是亚甲基或羰基; T是-O-,-N(R) - , - N(OR) - , - N(NHCOR) - ,-N(N = CHR) - 或-N(NHR) - ,其中R是如上定义的H或Ra,条件是当L是亚甲基时,T是-O-; Z和Y之一是H 另一个是OH,保护的OH或氨基,单或二烷基氨基,保护的氨基或氨基杂环,或Z和Y一起为= O,= NOH或衍生的肟;包括其任何药学上可接受的盐和任何立体异构形式, 其立体异构形式的混合物是抗微生物剂。

    BLUNT ROLLING METHOD AND DEVICES
    53.
    发明申请

    公开(公告)号:US20190297936A1

    公开(公告)日:2019-10-03

    申请号:US15940614

    申请日:2018-03-29

    Abstract: The embodiments disclose a method including creating a blunt rolling device for rolling blunt smoking products, rolling a wrapper on a wrapper roller tube to create a blunt wrapper tube with a glass tip, tamping smoking material into the blunt wrapper tube at a user defined density, twisting, cutting and tucking wrapper excess into the glass tip, and controlling the operations of the blunt rolling device using a computer, wireless communications and a blunt rolling method and device program for sequencing processes, operating solenoid drive motors and humidity and temperature devices of a smoking material humidor, adjusting settings of devices using predetermined data stored in digital memory devices and accessed using digital processors.

    Cell counting systems and methods
    54.
    发明授权
    Cell counting systems and methods 有权
    细胞计数系统和方法

    公开(公告)号:US09354155B2

    公开(公告)日:2016-05-31

    申请号:US13483771

    申请日:2012-05-30

    CPC classification number: G01N15/1463 G01N2015/1006

    Abstract: An automated system captures multiple digital images of a sample, from different viewing areas of the sample. The images are analyzed and a test result may be reported based on the count of cells in all of the digital images. The system may be especially applicable to the testing of samples having low cell concentrations, as the variability between tests may be reduced as compared with a system that bases its test results on only a single image of the sample. The system may count the cells in a first digital image of the sample, and may capture or analyze one or more additional digital images only when it is recognized that additional measurements are needed to ensure adequate accuracy and repeatability of the test.

    Abstract translation: 自动化系统从样品的不同观察区域捕获样品的多个数字图像。 分析图像,并且可以基于所有数字图像中的单元的计数来报告测试结果。 该系统可能特别适用于具有低细胞浓度的样品的测试,因为与将其测试结果仅基于样品的单个图​​像的系统相比,可以减少测试之间的可变性。 系统可以对样本的第一数字图像中的单元进行计数,并且可以仅在认识到需要额外的测量以确保测试的足够的精度和可重复性时才捕获或分析一个或多个附加的数字图像。

    THERMAL BLOCK WITH BUILT-IN THERMOELECTRIC ELEMENTS
    57.
    发明申请
    THERMAL BLOCK WITH BUILT-IN THERMOELECTRIC ELEMENTS 审中-公开
    具有内置热电元件的热块

    公开(公告)号:US20130137144A1

    公开(公告)日:2013-05-30

    申请号:US13487414

    申请日:2012-06-04

    Abstract: Rapid and uniform temperature changes in the wells of a microplate or any thin-walled plate that contains an array of reaction wells, or in the channels of a multi-channel microfluidics device, are achieved by the use of a thermal block with thermoelectric heating/cooling elements built into the block, or by the use of a thermal block with wedges protruding from its lower surface, with thermoelectric elements placed in surface contact with the angled sides of each wedge.

    Abstract translation: 在微孔板或包含反应孔阵列的任何薄壁板或多通道微流体装置的通道中的孔中的快速和均匀的温度变化通过使用具有热电加热/ 或者通过使用具有从其下表面突出的楔形物的热块,其中热电元件与每个楔形物的倾斜侧面表面接触。

    Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
    59.
    发明授权
    Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) 有权
    聚(ADP-核糖)聚合酶(PARP)的二氢吡喃并酞嗪酮抑制剂

    公开(公告)号:US08012976B2

    公开(公告)日:2011-09-06

    申请号:US12510096

    申请日:2009-07-27

    Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

    Abstract translation: 具有式(I)和式(II)所示结构的化合物:其中取代基Y,Z,A,B,R 1,R 2,R 3,R 4和R 5如本文所定义。 本文提供了聚(ADP-核糖)聚合酶活性的抑制剂。 本文还描述了包含本文所述的至少一种化合物和本文所述的化合物或药物组合物用于治疗通过抑制PARP活性而改善的疾病,病症和病症的药物组合物。

Patent Agency Ranking